MindBio Therapeutics Corp.
MBIO
CNSX
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 104.50% | -25.37% | |||
| Depreciation & Amortization | -- | 100.35% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 100.01% | -19.25% | |||
| Operating Income | -100.01% | 19.25% | |||
| Income Before Tax | -100.67% | 14.07% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -100.67% | 14.07% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -66.67% | 90.91% | |||
| Net Income | -100.66% | 14.33% | |||
| EBIT | -100.01% | 19.25% | |||
| EBITDA | -- | 19.27% | |||
| EPS Basic | -16.77% | -4.08% | |||
| Normalized Basic EPS | -16.77% | 22.35% | |||
| EPS Diluted | -16.77% | -4.08% | |||
| Normalized Diluted EPS | 57.30% | 22.35% | |||
| Average Basic Shares Outstanding | 71.83% | -17.69% | |||
| Average Diluted Shares Outstanding | 369.89% | -17.69% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||